Add your feed to SetSticker.com! Promote your sites and attract more customers. It costs only 100 EUROS per YEAR.
Pleasant surprises on every page! Discover new articles, displayed randomly throughout the site. Interesting content, always a click away
Knipper
Healthcare Support SolutionsKnippeRx and RxLightning Partner to Streamline Provider Experience and Accelerate Patient Access to Specialty Medications 28 Mar 2024, 7:21 pm
NEW ALBANY, Ind. — RxLightning, creator of the industry’s first comprehensive platform for streamlining specialty medication access and affordability, and KnippeRx, a leader in custom pharmacy solutions and Patient Assistance Program services, are excited to announce a strategic partnership aimed at simplifying the specialty medication onboarding process for patients and providers.
Through a co-branded and integrated web portal, RxLightning now enables prescribers and their care teams the ability to enroll patients in Free-Drug and Patient Assistance Programs (PAP) managed by KnippeRx. KnippeRx supports a number of PAP initiatives for prominent pharmaceutical manufacturers by offering application management, patient qualification, product dispensing, and patient support. To start, the two companies launched an embedded, digital enrollment process for over a dozen commonly prescribed medications, with new medications being added in subsequent months.
Previously, enrolling in some manufacturer programs required paper forms, snail-mail, or fax, and could take weeks to be processed. Now, PAP submission times through the RxLightning portal and KnippeRx Cares Technology Ecosystem are reduced to a matter of minutes, significantly improving the time it takes for patients to receive medications. By eliminating the need for cumbersome paperwork and providing real-time status updates on enrollments, stakeholders have complete visibility into the progress of each patient’s journey. This ensures that service teams are alerted to access hurdles in near real-time and can effectively support speed-to-therapy.
“We are thrilled to partner with RxLightning to transform the specialty medication enrollment experience,” said Luke Austin, VP of Patient Support at KnippeRx. “Together, by delivering a fully-digital enrollment workflow to patients and providers, we can accelerate access to quality care while ensuring patients receive support for the medications they need.”
The partnership has seen early successes, with prominent health systems and physician practices completing enrollments through the streamlined workflow and enhanced digital experience. KnippeRx and RxLightning are committed to expanding the value they deliver by growing the number of medications available within the platform, with more manufacturers looking to embrace digital specialty medication enrollment capabilities every day.
Julia Regan, Founder and CEO of RxLightning, added, “This partnership is only the beginning, and is a significant step forward in our mission to simplify and expedite access to critical medications. Together, KnippeRx and RxLightning are committed to creating a seamless and efficient enrollment process that benefits both patients and providers.”
To learn more about how RxLightning’s solutions can simplify and automate your team’s medication access and affordability processes, please reach out today. To learn more about how KnippeRx PAP Solutions can provide increased efficiency and an improved patient and HCP experience, please contact info@knipperx.com or call 1-85-KNIPPERX (1-855-647-7379).
About Knipper Health
Knipper Health is a leading health care solutions company serving the pharmaceutical, biotechnology and medical device industries for more than 35 years, with a focus on Sample Management and Marketing, Custom Pharmacy Solutions and 3PL services. Knipper has become the single source-provider of samples management services for many small, to large pharmaceutical customers. KnippeRx is a highly nimble, independent specialty pharmacy that serves both commercial and non-commercial needs. KnippeRx helps overcome the complex barriers to patient access by providing the shortest path from initiation of a prescription to delivery of essential therapy. Knipper 3PL provides storage and distribution of CRT, Cold Chain, Frozen and DEA III-V products along with full order to cash, chargebacks and contract management services.
About RxLightning
RxLightning digitizes, automates, and streamlines the historically manual specialty medication onboarding process. With RxLightning, providers can quickly and easily complete patient enrollment for every specialty medication in every therapeutic area, helping reduce paperwork, streamline communication, and accelerate speed-to-therapy. Through the company’s MedAccess Ecosystem, patients, providers, specialty pharmacies, and pharmaceutical manufacturers have insights into each step of the patient onboarding journey. Learn more at rxlightning.com.
The post KnippeRx and RxLightning Partner to Streamline Provider Experience and Accelerate Patient Access to Specialty Medications appeared first on Knipper.
KnippeRx Receives URAC Accreditation for Specialty Pharmacy 6 Nov 2023, 10:13 pm
(Louisville, KY and Charlestown, IN – November 6, 2023) – KnippeRx, a division of Knipper Health, is proud to announce that KnippeRx has earned URAC accreditation for Specialty Pharmacy. URAC is the independent leader in promoting health care quality by setting high standards for clinical practice, consumer protections, performance measurement, operations infrastructure, and risk management. By achieving this status, KnippeRx has demonstrated its commitment to quality care, enhanced processes, patient safety and improved outcomes.
At a time when brands continue to face access and reimbursement challenges due to shrinking drug formularies, increased generic competition, and higher distribution costs, KnippeRx provides an alternative to the traditional pharmacy model with specialized services that feature a personalized, focused, and responsive approach to helping patients receive treatment—quicker and hassle-free. KnippeRx patient-centric pharmacy that leverages ongoing patient education, innovative technology, and one-on-one patient assistance to serve manufacturers, patients, providers, and payers in a way that’s never been done in the specialty care environment.
“At KnippeRx, we are proud to have earned URAC accreditation for specialty pharmacy, which accentuates our commitment to providing high quality pharmacy solutions for improving patient lives, enabling patients to receive needed medications through an exceptional patient experience and streamlined patient journey, thus creating the shortest path between patient and therapy” said Michael Laferrera, CEO Knipper Health.
KnippeRx commercial and non-commercial solutions are designed to ensure patients get the medication they need when they need it—despite growing market complexities, distribution challenges, and insurance obstacles—while creating a seamless experience that improves patient outcomes. As an affiliate of Knipper Health with advanced operational and logistical expertise, KnippeRx is uniquely positioned to offer seamless, integrated solutions that address a wide range of patient access and specialty drug distribution challenges.
“Now more than ever, specialty pharmacies are an essential part of the patient care team and patient experience. URAC congratulates KnippeRx on their achievement of Specialty Pharmacy Accreditation. This achievement demonstrates excellence in pharmacy operations, product handling, patient education, and patient management. When an organization achieves URAC accreditation, they demonstrate their commitment to improving their quality of care, which is important to patients, providers, and payers,” said URAC’s President and CEO Shawn Griffin, MD.
About Knipper Health
Knipper Health, is a leading healthcare solutions company serving the pharmaceutical, biotechnology, and medical device industries for more than 35 years, with a focus on Sample Management and Marketing, Custom Pharmacy Solutions and 3PL services.
Knipper Health, the nation’s largest supplier of end-to-end pharmaceutical samples, formed KnippeRx to help overcome the barriers that hinder patients’ access to critical therapies. KnippeRx is a highly nimble, independent specialty pharmacy that aims to create the shortest path between patients and therapy in an evolving and increasingly complex commercial drug environment.
About URAC
Founded in 1990 as a non-profit organization, URAC is the independent leader in promoting health care quality and patient safety through renowned accreditation programs. URAC develops its evidence-based standards in collaboration with a wide array of stakeholders and industry experts. The company’s portfolio of accreditation and certification programs span the health care industry, addressing health care management and operations, pharmacies, telehealth, health plans, medical practices and more. URAC accreditation is a symbol of excellence for organizations to showcase their validated commitment to quality and accountability.
Media Contact:
Teresita Weiss
teresita.weiss@knipper.com
The post KnippeRx Receives URAC Accreditation for Specialty Pharmacy appeared first on Knipper.
Direct-to-Patient Sample Distribution in the Time of COVID-19 31 Oct 2023, 1:02 pm
By John C. Petrolino & John Maher
The Public Health Emergency (PHE) allowed for a temporary abeyance of the Prescription Drug Marketing Act’s (PDMA’s) requirement that drug samples be provided to physicians prior to subsequent distribution to patients. The ability for physicians to direct drug companies to provide samples directly to patients leverages accepted telehealth platforms while maintaining necessary oversight of the physician as learned intermediary. Defining compliant sample distribution pathways that protect patients and their personal information assures technological solutions can persist beyond the expiration of the PHE.
The COVID-19 pandemic strained global healthcare systems in a way that had not previously been seen in the modern era. In the face of unprecedented demand to create new pathways to allow patients and healthcare providers continued access to healthcare resources, the declaration of the Public Health Emergency by the U.S. Department of Health and Human Services (HHS) on January 31, 2020 opened the door more widely to, among other things, utilization of telehealth services.
As the use of these services proliferated, a secondary benefit of the PHE was realized in the temporary suspension of the PDMA’s requirement that drug samples be provided only to licensed healthcare providers with the capacity to prescribe the drugs in question, thereby allowing drug samples to be delivered directly to patients.[1] By removing the federal requirement that samples need to be physically delivered to a healthcare provider’s office before getting to a patient, the benefits of drug sampling—to assess safety and efficacy in a given patient prior to prescribing a full course of therapy—were preserved during a period when many offices were closed to patient visits. However, despite the availability of this pathway, experience confirmed that many pharmaceutical companies were reluctant to distribute samples directly to patients. Novel pathways can understandably create hesitancy. Notwithstanding the U.S. Food and Drug Administration’s (FDA’s) clear removal of the previous regulatory injunction on shipping pharmaceutical products directly to patients, many pharmaceutical companies could not overcome perceived unknown risks in the direct-to-patient novel sampling pathway, particularly where pharmaceutical manufacturers long ago accepted the restrictions as marketing dogma.
In order to appreciate the cautious approach taken by pharmaceutical companies who distribute samples, it is important to understand the regulatory landscape that frames drug sample distribution. The provision of drug samples to healthcare providers and patients is governed by various federal and state laws, most directly the PDMA. The PDMA governs the interstate commerce aspect of sample distribution, while state laws and regulations govern how healthcare providers may distribute to patients as a function of the practice of medicine.[2]
Prior to the implementation of the PHE, the PDMA only allowed “drug samples . . . [to] be distributed by a manufacturer or its authorized distributor of record to a practitioner licensed to prescribe the drug that is to be sampled.”[3] This was an effective prohibition on direct-to-patient (DTPt) distribution of samples, which rightly served to ensure that the learned intermediary controlled who received prescription therapy. However, in the age of telehealth, the need for the physical transfer of samples from healthcare provider to patient seems anachronistic, particularly when full courses of the very same therapy can be prescribed as a result of a telehealth visit.
As such, the suspension of enforcement of the de facto prohibition on DTPt samples seemed to further the legitimate objective behind drug sampling—determining if a particular therapy will be effective for a particular patient before a full course is prescribed, ostensibly saving precious healthcare dollars from being spent where no benefit is likely to be seen. Given that drug sampling is a promotional tool leveraged by most pharmaceutical manufacturers, it would seem that an opportunity to continue sample fulfillment during a time of restricted healthcare provider office access would be extremely attractive.
Given the abeyance of the PDMA restriction on DTPt sample distribution, companies turned their scrutiny to the potential impact of the 1996 Heath Insurance Portability and Accountability Act (HIPAA) strictures. Pharmaceutical manufacturers may be unfamiliar with the nuances of HIPAA for the simple reason that, in the large majority of instances, it simply does not apply to their activities. Per the statute, HIPAA only applies to defined “covered entities” and “business associates,” definitions within which pharmaceutical companies generally do not fall.
To wit, the definition of “covered entities” encompasses those “healthcare providers” who provide medical or health services commonly furnished in physicians’ offices and rendered without charge or included in the physicians’ bills.[4] Manufacturers and sample fulfilment providers have never been considered covered entities because distributing samples to healthcare providers is not considered to constitute the provision of medical services. Samples, rather, are provided to patients by healthcare providers incidental to the physicians’ course of diagnosis or treatment of an injury or illness provided in the physicians’ offices.[5]
Similarly, the definition of “business associates” are those parties who, “on behalf of such covered entity,” provide a covered function or activity regulated by HIPAA that involves the use of personal health information to help the covered entity carry out its health care activities and functions.[6] According to HHS, business associate functions and activities include: claims processing or administration; data analysis, processing, or administration; utilization review; quality assurance; billing; benefit management; practice management; and repricing.[7] In essence, to be a business associate, the entity in question must be providing a service for the covered entity (that the covered entity could provide directly to its patients) or the entity must be providing a service to the covered entity that involves the use of protected health information. Manufacturers and sample fulfilment providers have, historically, never been considered business associates of the healthcare providers requesting drug samples because sample distribution is not a covered function (as noted above) and, previously, did not rely on the personal information of a patient.
However, in the context of DTPt sample distribution, this equation seems to change on its face because the sample fulfilment provider is now using personally identifiable information (PII)—e.g., name and address—in order to provide samples to patients on behalf of the manufacturer and at the direction of the healthcare provider. This potentially brings those parties within the ambit of the “business associate” definition. While the distinguishing factors could reasonably be seen to change the outcome, it is an entirely defensible position to state that the use of PII on behalf of the manufacturer for sampling purposes does not result in a business associate relationship.
As noted above, and per the definition of “business associate,” the manufacturer and sample fulfilment provider remain absent from the covered function, which would be necessary to implicate HIPAA applicability, i.e., the healthcare provider’s provision of medical or health services furnished in their offices. Despite the facial inapplicability of HIPAA to manufacturers and sample fulfilment providers in the DTPt continuum, additional risk mitigation measures could include establishing a process that: a) limits the flow and exchange of patient information to a HIPAA minimum-necessary standard; b) limits access and—to the extent possible—isolates patient data to confined components of electronic sampling platforms; c) electronically restricts manufacturer access to patient data (generally through the use of a third-party fulfillment agent); and d) for manufacturers who are still concerned that DTPt programs might bring manufacturers or sample fulfilment providers within the reach of HIPAA, require that healthcare providers (prior to sending patient data to a sample service agent) attest that the healthcare provider has the necessary authorization and/or consent to provide patient data to the sample fulfilment provider (as a non-covered entity).[8]
As healthcare providers of all stripes embrace the advances in science and technology and leverage them to the benefit of patients, it is imperative that the regulatory landscape facilitate these improving outcomes. Unfortunately, as is the nature of the healthcare regulatory process, changes come slowly while patients and healthcare providers labor under increasingly labyrinthine processes and archaic rules that stand in the way of efficient delivery of healthcare services. The PHE stands as a rare example of regulators exercising a nimbleness of thought and an embracing of technological solutions that inure to the benefit of all healthcare providers and consumers.
Unfortunately, when the PHE expires, those same beneficiaries will be thrust back into the constraints that were forged in the PDMA that require the physical handing of samples from provider to patient. While it would take an act of Congress to modify the PDMA, the pharmaceutical industry has proven itself to be one of the most effective advocates for changes to healthcare regulations. If the industry can coax the codification of DTPt delivery of samples, another roadblock to effective efficient care for patients will have been removed, and patients can reap the benefits. With the ubiquity of home delivery of medicines firmly in place, the time for DTPt delivery of drug samples is clearly at hand.
The post Direct-to-Patient Sample Distribution in the Time of COVID-19 appeared first on Knipper.
Knipper Health appoints William “Bill” Fletcher as Senior Director 17 Jul 2023, 3:26 pm
(Lakewood, NJ — July 5, 2023) – Knipper Health appoints William “Bill” Fletcher as Senior Director, Traceability and Electronic Client Communications.
Industry expert in serialization and traceability joins Knipper Health’s leadership team to drive compliance and expand services.
Knipper Health, a leading health care solutions company serving the pharmaceutical, biotechnology and medical device industries, appointed William “Bill” Fletcher as its Senior Director, Traceability and Electronic Client Communications.
“Bill’s extensive experience and deep subject matter expertise in the life sciences, biotechnology and pharmaceutical industries, especially in the areas of serialization, traceability and electronic data interchange (EDI), adds to our already seasoned team,” said Chris Dillon, general manager of Knipper 3PL, Knipper’s business dedicated to third-party logistics (3PL).
Fletcher is an experienced executive with a 41-plus year history in the life sciences industry, with leadership roles in pharmaceutical and biotech packaging and labeling, research and development, warehousing, distribution and medical devices. His previous roles have included chief technology officer, director of development, product director and program director for software, hardware and online solutions in life sciences.
For 18 years before joining Knipper Health, Fletcher was managing director of Pharma Logic Solutions, LLC, a consulting company that specializes in compliance with global traceability and serialization regulations. He has assisted over 65 manufacturers, wholesalers and 3PL and distribution providers to implement serialization systems, packaging, labeling and related procedures—including several of the world’s largest drug or distribution providers—with both internal or contracted manufacturing, packaging and distribution.
For decades, Fletcher has spoken to audiences of hundreds during industry events around the world and across the United States. In 2013, he was asked to share his experience by speaking in the U.S. Capitol to congressional staff developing the Federal Drug Quality and Security Act (DQSA) of 2013, and more specifically, its Title II, the Drug Supply Chain Security Act (DSCSA), to improve the integrity of the U.S. drug supply chain and foster greater patient safety.
“I am excited to be a contributor for Knipper Health and Knipper 3PL and have already felt the great sense of community here with my colleagues,” Fletcher said. “This is a great time to join the company as we aim to solve many of the industry’s challenges with serialization and DQSA/DSCSA compliance and expand our services around the secure exchange of needed medications.”
The appointment of Fletcher further demonstrates Knipper Health’s strong desire to have highly experienced top leadership embedded in each area of business to ensure continued achievement of industry-best client satisfaction while driving aggressive revenue goals.
About Knipper Health
Knipper Health is a leading health care solutions company serving the pharmaceutical, biotechnology and medical device industries for more than 35 years, with a focus on Sample Management and Marketing, Custom Pharmacy Solutions and 3PL services. Knipper has become the single source-provider of samples management services for many small, to large pharmaceutical customers. KnippeRx is a highly nimble, independent specialty pharmacy that serves both commercial and non-commercial needs. KnippeRx helps overcome the complex barriers to patient access by providing the shortest path from initiation of a prescription to delivery of essential therapy. Knipper 3PL provides storage and distribution of CRT, Cold Chain, Frozen and DEA III-V products along with full order to cash, chargebacks and contract management services.
Media Contact:
Marilyn Aquino
MAquino@proximylhealth.com
The post Knipper Health appoints William “Bill” Fletcher as Senior Director appeared first on Knipper.
Todd Phillips, CFO 9 Mar 2023, 7:34 pm
(Lakewood, NJ—March 2023) – Knipper Health, a leading healthcare solutions company serving the pharmaceutical, biotechnology, and medical device industries, appointed Todd Phillips as Chief Financial Officer February 1st.
“Todd is a seasoned financial professional with deep expertise in the field. His impressive record of achievements as an executive leader makes him a great fit for Knipper Health as we grow our existing business lines,” said Mike Laferrera, Knipper President and CEO.
Mr. Phillips is an experienced executive with a 25+ year history with a unique blend of executive, finance, and operational roles, primarily with private equity backed organizations.
He most recently served as a board member and operating partner on various portfolio companies for a private equity firm with over $1 billion under management, where he led pre- and post-merger activities, carve-outs/divestitures, change management, capital markets, and financial modeling/analysis and system implementation. Todd led complex carve-outs from both public and private companies including transaction service agreement negotiations and stand-up implementation.
Previously roles included CEO, CFO and COO. Todd ran global operations, overseeing the strategic and daily operations for a leading fluid reprocessing company. He also served as CEO for a metal processing business where he led a complete strategic review and turnaround. Also, in a previous position as CFO, Todd led the professionalization and subsequent international expansion for a leading global provider of real-time data and intelligence for commodity and energy markets.
“I am excited to be a part of Knipper Health and have already felt the great sense of community here with my colleagues,” said Mr. Phillips. “This is a great time to join the company as we aim for aggressive growth in 2023 and beyond, across all business units.”
The appointment of Mr. Phillips further demonstrates Knipper Health’s strong desire to have top leadership embedded in each area of our business to ensure continued achievement of industry-best client satisfaction while driving aggressive revenue goals.
The post Todd Phillips, CFO appeared first on Knipper.
Knipper Health Will Be Sponsoring the 30th Annual Sharing Conference™, May 17th – 19th at the MGM National Harbor, in Oxon Hill, MD 5 May 2022, 8:24 pm
Knipper Marketing and Sample Management (MSM), a Knipper Health Company, will once again be an exhibitor and an active contributor to this industry-wide event. Eric Johnson, Chief Commercial Growth Officer at Knipper Health will be presenting and participating in a panel discussion, “Sample Distribution Models, Where We Are and Where We’re Going” alongside Devang Modi from Bausch Healthcare, and Steve Conn from Genesis Life Science Logistics.
The Sharing Conference is a not-for-profit organization dedicated to the ongoing education of its members on compliance best practices within the pharmaceutical, medical device, and biotech industries.
Learn about the many changes and how to maintain operational efficiency and regulatory compliance.
There’s still time to register: https://sharingalliance.org/registration-information/
The post Knipper Health Will Be Sponsoring the 30th Annual Sharing Conference™, May 17th – 19th at the MGM National Harbor, in Oxon Hill, MD appeared first on Knipper.
J. Knipper and Company Marks Its 35th Anniversary with New Knipper Health Name to Better Represent Their Expanding Range of Healthcare Support and Solutions 2 Mar 2022, 6:48 pm
(Lakewood, NJ—March 2022) – J. Knipper and Company, a leading healthcare solutions company serving the pharmaceutical, biotechnology, and medical device industries for more than 35 years, has announced it is evolving its name to Knipper Health, to reflect its expanding commitment to healthcare support solutions and its expertise in driving the innovations needed to help shape the future of healthcare.
“For manufacturers, practitioners and patients alike, creating the shortest path between patient and therapy is paramount,” states Mike Laferrera, President and CEO of Knipper Health. “As a company that has been at the forefront of developing innovative programs and services for three-and-a-half decades, our new name serves as a constant reminder of our never-ending mission to meet and surpass the needs of our partners and stakeholders.”
In addition to the corporate name change, each of the company’s affiliated business units, Knipper Marketing & Sample Management (Knipper MSM), Knipper Third Party Logistics (Knipper 3PL), and KnippeRx Custom Pharmacy Solutions (KnippeRx) will also be receiving a brand refresh that aligns with the new corporate positioning to better represent their association in offering comprehensive solutions, for manufacturers, practitioners, and patients alike.
An acknowledged leader in the sample management channel, the Knipper Marketing & Sample Management (MSM) business unit continues to expand the scope of its service offerings, including Samplicity, the industry’s only fully integrated sample management platform, which features a one resource, one team, one point-of-contact approach, and a unique suite of operational services and technical advancements.
“Today’s health care environment demands services and programs that create the shortest path between patient and therapy,” continues Laferrera. “The expansion of our Knipper 3PL business unit and acquisition of Eagle Pharmacy are just two of the many enhancements we have made to ensure that those demands are met.”
KnippeRx, the custom pharmacy solutions business unit of Knipper Health, is purpose-built to help patients eliminate obstacles and provide the shortest path possible from initiation of their script to delivery of their essential therapy. Knipper’s Custom Pharmacy Solutions business unit helps patients overcome obstacles, to access clinical care, while leveraging cutting-edge technology and make a commitment to deliver, “Care. At the Speed of Need.” Knipper Health has complemented the resources and services of this business unit with the acquisition of Eagle Pharmacy, a direct-to-patient pharmacy that offers numerous manufacturer programs, each uniquely suited for patients who prefer to take brand name medication but lack affordable access.
As a recent demonstration of its commitment to total healthcare support solutions, Knipper Health has expanded the scope of its third-party logistics unit, Knipper 3PL, to include trade-focused warehousing and distribution with advanced technology and innovation that can dramatically improve the efficiency and performance of a company’s entire supply chain. The Knipper 3PL solutions are agile and highly scalable, so programs can be tailored to a company’s scope, timeline, and budget, with end-to-end fulfilment distribution and logistics capabilities, while maintaining impeccable regulatory compliance.
The recent expansions of its business units and healthcare support services offer a snapshot of the company’s broadening industry leadership and with the assistance of Court Square Capital Partners it expects to continue its proactive search to either build or acquire additional services and capabilities that align with the Knipper Health vision to deliver care at the speed of need.
“As we celebrate our 35th Anniversary, the new Knipper Health name exemplifies these most recent activities, which are in response the growing needs of our valued customers,” concludes Laferrera. “And as we look forward to the next 35 years, we remain passionately committed to keeping pace with the ever-changing market demands by “Leading the way to smarter solutions.”
The post J. Knipper and Company Marks Its 35th Anniversary with New Knipper Health Name to Better Represent Their Expanding Range of Healthcare Support and Solutions appeared first on Knipper.
J. Knipper and Company Featured in Latest Supply Chain World Magazine 17 Feb 2022, 2:38 pm
Based in Lakewood, New Jersey, J. Knipper and Company is on a mission to service the life science, pharmaceuticals, and healthcare industries with logistics capabilities and state-of-the-art systems, which guarantee customer satisfaction. Now celebrating its 35th anniversary, Supply Chain World speaks with Knipper leadership team to reflect on the company’s past achievements, and the success yet to come.
Impressive developments have taken place the past 5 years. In 2016, Knipper opened a Midwest distribution facility located in Charlestown, Indiana. This facility is centrally located and can expedite shipments to any destination point in the US. In 2017, the company established its custom pharmacy solutions business unit, KnipperRx. This independent specialty pharmacy was designed to help companies overcome the complex barriers that often hinder patient access to drugs. At the start of 2020, Knipper acquired Eagle Pharmacy, which helped manufacturers overcome obstacles that prevent or delay patients from accessing the therapy they need. In 2021, Knipper expanded the Midwest facility to address the growing needs of its customers.
Throughout its tenure, the company has assembled a noteworthy group of offerings for its customers. With Knipper Marketing and Samples Management business unit and Knipper 3rd Party Logistics, they were able to focus on distributing pharmaceutical samples to physicians, which than leads to samples in patients’ hands. One aspect that Knipper is incredibly proud of is its capability to redefine its services over the years, investing heavily in advanced technologies to offer the best-in-class systems. Another key differentiator, as Senior Vice President of Operations, Vic Ricci, expresses, is the advanced technology implemented regularly over many years to help the company further increase its efficiency. “We provide unique, tailored solution for each and every client.”
As Knipper celebrates its 35th anniversary, the company is excited about the future and potential that lies within their company to serve the ever-expanding needs of the health care industry.
The post J. Knipper and Company Featured in Latest Supply Chain World Magazine appeared first on Knipper.
J. Knipper and Company, Inc. Announces Completion of Expansion at Charlestown, IN. Facility. 4 Jan 2022, 6:58 pm
(Charlestown, IN., January 2022) J. Knipper and Company, Inc. (Knipper), recently announced the completion of its expansion to the current Knipper distribution center at 1250 Patrol Road, Charlestown, IN. Knipper has made a firm commitment to the growth and development of their 3PL capabilities with solutions that are agile and scalable, tailoring a program for the precise scope, timeline, and budget to meet the evolving needs of customers. The enlargement of this facility adds an additional 150,000-square-feet of space, which provides an additional refrigeration capacity of 1,500 pallets and a drive-in freezer, allowing Knipper 3PL to accommodate larger clients. The location of this facility is centrally located for convenient shipping to any part of the country and the expansion allows Knipper to enhance their 3PL services while continuing to deliver unsurpassed performance, value, and results. Knipper offers custom pharmacy solutions, complete supply chain services to the U.S. pharmaceutical industry and is the largest provider of samples management services.
“This expansion of our Charlestown, IN. facility reflects our ongoing commitment to client-focused solutions that are developed and implemented to ensure maximum return on their investments, and ultimately to improve people’s lives,” stated Knipper President & CEO, Mike Laferrera. “We greatly appreciate the State of Indiana, the City of Charlestown, River Ridge Commerce Center, and One Southern Indiana (1si) for their efforts in helping us expand to meet new demands.”
Founded in 1986 and celebrating its 35th Anniversary, J. Knipper and Company, Inc. is headquartered in Lakewood, N.J. and established its Charlestown distribution center in 2016. Known for being an integral part of the communities in which it is located, Knipper has been awarded the Clara Barton Corporate Humanitarian Award by the American Red Cross and the Corporate Citizen of the Year award by Catholic Charities for volunteer efforts by Knipper employees.
“The City of Charlestown is fortunate to have great companies like J. Knipper providing opportunities for our residents in the region,” commented Treva Hodges, PhD, Mayor of Charlestown, Ind. “This expansion is an exciting indication of the endless possibilities that are currently found in the River Ridge Commerce Center not only for new, but for existing businesses. We’re thrilled to see the growth.”
Located between Charlestown and Jeffersonville, IN, Knipper’s facility is situated in the River Ridge Commerce Center, a world-class 6,000-acre business and manufacturing park under development along the Ohio River, across from Louisville, KY. Recently, the River Ridge Commerce Center reported increased employment, expanded development, and generated an increase of $2.5 billion in economic output in 2019 alone — the largest output from the business park since it opened.
“On behalf of the entire River Ridge community, I want to compliment J. Knipper and Company for its continued growth and success,” said River Ridge Executive Director Jerry Acy. “We are very pleased that the company has continued to grow at the River Ridge Commerce Center and make this its Southern Indiana home. Knipper is the type of innovative, growth-oriented employer we value and very much appreciate. They have an important role in serving the nation’s healthcare and pharmaceutical industries, and we are glad to support their success.”
Wendy Dant Chesser, CEcD, President and CEO, One Southern Indiana (1si), added, “With Knipper’s second expansion since the initial build in 2016, we are excited about their continued investment into our Southern Indiana Community. 1si looks forward to working with them in the future.”
The post J. Knipper and Company, Inc. Announces Completion of Expansion at Charlestown, IN. Facility. appeared first on Knipper.
Knipper’s New SamplicitySA is the Next Generation of Sample Management 3 Aug 2021, 1:40 pm
(Lakewood, NJ – August 2021) – J. Knipper and Company, a leading healthcare solutions company serving the pharmaceutical, biotechnology and medical device industries, is announcing the introduction of SamplicitySA, an enhanced Sample Inventory Management System. With its many advancements, the user-friendly SamplicitySA creates greater operational efficiencies and provides a simplified and more intuitive user experience, keeping users more informed and compliant than ever before.
One of the most unique features of SamplicitySA is a robust yet, easy-to-use Compliance Scorecard, which collects and reports on a full-range of information in key, compliance-driven areas. Highly configurable, SamplicitySA generates data sets collected on regional, district, and specific sales representative levels. With this enhanced analytical power, users can easily review the timeliness of shipment acknowledgements, signature audit responses, reconciliation items, theft/losses in the field, delayed inventory submissions and much more. The Compliance Scorecard has several different charts available and is a great way to show and track metric trends over time.
“In developing our new SamplicitySA system, Knipper included input from both our clients and internal stakeholders,” states Knipper’s Chief Commerical Growth Officer, Eric Johnson. “One of our key goals was to create the quickest path to get users to the data they need, which is precisely what we’ve been able to achieve.” Featuring simplified navigation, the SamplicitySA Dashboard provides faster, more complete visibility and transparency across the entire Sample Accountability Program, while delivering deeper analysis and evaluation of the overall samples program.
SamplicitySA Sample Management is an integral component of Samplicity, Knipper’s fully-integrated sample management platform. As a one-of-a-kind suite of products, services and support, Samplicity satisfies a full-range of sampling program requirements, serving the needs of pharmaceutical manufacturers, practitioners and patients.]
The platform helps clients achieve their goals more economically and with fewer resources. Sales personnel can spend their time selling rather than managing their sample orders, or the sample requests of their customers. Marketing Directors benefit from Samplicity’s intuitive Dashboard to expand sample programs effectively and cost efficiently. Finally, emerging companies can take advantage of Samplicity’s multiple functions to avoid managing multiple suppliers and subsequently reduce costs.
Eric Johnson concludes, “Users will discover that the SamplicitySA graphical presentation of data and its modern user interface (UI) deliver a highly intuitive look and feel that enhances experience and dramatically simplifies navigation.”
Knipper is currently scheduling demonstrations of the new SamplicitySA Sample Accountability program. Interested parties are asked to contact Eric Johnson via email at eric.johnson@knipper.com or by calling 732-987-7151.
The post Knipper’s New SamplicitySA is the Next Generation of Sample Management appeared first on Knipper.